Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

50.05 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55,871
Open 50.05
Bid (Size) 49.88 (13)
Ask (Size) 49.90 (3)
Prev. Close 50.05
Today's Range 50.05 - 50.05
52wk Range 42.64 - 55.72
Shares Outstanding 1,250,690,553
Dividend Yield 3.80%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stable Blue-Chip Stocks to Buy Before Earnings Season
Don't miss out on these stable blue-chip stocks to buy now. Explore their potential for steady returns and long-term portfolio growth. 
Via InvestorPlace
Senate To Review Novo Nordisk's Levemir Insulin Discontinuation
Novo Nordisk will meet with U.S. Senate aides to discuss the discontinuation of Levemir, its long-acting insulin, amid concerns about manufacturing constraints and patient access. Senators press for... 
Via Benzinga

Performance

YTD
+0.10%
+0.10%
1 Month
+5.84%
+5.84%
3 Month
+9.28%
+9.28%
6 Month
-2.93%
-2.93%
1 Year
-5.37%
-5.37%

More News

Read More
Sanofi's $20B Consumer Health Unit Sale: Goldman Sachs, Morgan Stanley Line Up $6.5B Financing
Via Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Via Benzinga
EXCLUSIVE: VeeCon 2024 Announces Danica Patrick, Jerome Bettis, Paul Scheer, Mike Posner, Liquid Death CEO Mike Cessario As New Speakers
Via Benzinga
3 Stocks to Sell Immediately Based on the French Election Results
Via InvestorPlace
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Via InvestorPlace
7 Safe Haven Stocks to Buy Before the Next Market Correction
Via InvestorPlace
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
Via Benzinga
Exposures Product Safety
Novavax’s Second Act: How a Fallen COVID Star Could Rise from the Ashes
Via InvestorPlace
Exposures COVID-19
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Via Benzinga
Where Will Novavax Be in 1 Year?
Via The Motley Fool
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
Via Benzinga
Exposures Product Safety
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
Via InvestorPlace
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Via Benzinga
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Is It Too Late to Buy Novavax Stock?
Via The Motley Fool
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
Via Investor's Business Daily
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Via Investor's Business Daily
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.